BACIL PHARMA LIMIT

Regd. Off.: 71, LAXMI BUILDING, 4TH FLOOR, SIR P. M. ROAD, FORT, MUMBAI 400 001.

Email ID: bacilpha@yahoo.com CIN: L24200MH1987PLC043427, Tel.: 22618452/22661541, Tel/Fax: 22618327

Audited Financial Results for the quarter and year ended 31st March 2014

(₹ In Lakhs)

		Quarter Ended Year Ended				
Sr. No.	Particulars	31/03/2014 (Unaudited)	31/12/2013 (Unaudited)	31/03/2013 (Unaudited)	31/03/2014 (Audited)	31/03/2013 (Audited)
1.	Income					- 100.05
	a) Net Sales/Income from Operations			51.75		106.35
	b) Other Operating Income					100.00
	Total Income			51.75		106.35
2.	Expenditure					
<u> </u>	a) Increase/decrease in stock and work in progress					39.00
	b) Consumption of raw materials					
	c) Purchase of traded goods		_	52.40		52.40
	d) Employees cost					
	e) Depreciation	0.18	0.02	0.02	0.57	0.07
	f) Other expenditure	9.70	2.23	6.14	16.15	18.13
	Total Expenditure	9.88	2.25	58.56	16.72	109.60
	Profit from Operations before Other Income, Interest and				16.70	- 3.25
3.	Exceptional Items (1-2)	- 9.88	- 2.25	- 6.81	- 16.72	1.11
4.	Other Income	1.74	0.90	0.66	5.82	- 2.14
5.	Profit before Interest and Exceptional Items (3+4)	- 8.14	- 1.35	- 6.15	- 10.90	- 2.14
6.	Interest					
7.	Profit after Interest but before Exceptional Items (5-6)	- 8.14	- 1.35	- 6.15	- 10.90	- 2.14
8.	Exceptional items					
9.	Profit (+)/ Loss (-) from Ordinary Activities before tax (7+8)	- 8.14	- 1.35	- 6.15	- 10.90	- 2.14
10.	Tax expense			0.30		- 0.20
11.	Net Profit (+)/ Loss (-) from Ordinary Activities after tax (9-10)	- 8.14	- 1.35	- 5.85	- 10.90	- 2.34
12.	Extraordinary Item (net of tax expense Rs)	_				
13.	Net Profit(+)/ Loss(-) for the period (11-12)	- 8.14	- 1.35	- 5.85	- 10.90	- 2.34
14.	Paid-up equity share capital (F.V. Rs.10/- per share)	589.00	589.00	589.00	589.00	589.00
15,	Reserve excluding Revaluation Reserves					
16.	Earnings Per Share (EPS)		<u> </u>			
10.	Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)			_	_	
,-	Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)					
17.	Public Shareholding	00.40.000	33,76,300	33,76,300	32,46,300	33,76,300
	- No. of shares	32,46,300		57.32%	55.12%	57.32%
	- Percentage of shareholding	55.12%	57.32%	31.3276	30.1270	
18.	Promoters and promoter group Shareholding		 	 	 	-
	a) Pledged/Encumbered	Nil	Nil	- Nil	Nil	Nil
	- Number of shares	NII	iNII			
	 Percentage of shares (as a % of the total shareholding of promoter and promoter group) 	Nil	Nil	Nil	Nil	Nil
	Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil
	b) Non-encumbered	00 40	05 43 700	25,13,700	26,43,700	25,13,700
	- Number of shares	26,43,700	25,13,700			
	 Percentage of shares (as a % of the total shareholding of promoter and promoter group) 	1	100.00%	100.00%	100.00%	100.00%
	Percentage of shares (as a % of the total share capital of the company)	44.88%	42.68%	42.68%	44.88%	42.68%

Note:

- The above results were reviewed by audit committee and taken on record by the Board of Directors of the Company in its meeting held on 1) May 30, 2014.
- 2) No activities were carried out at the plant of the company and the expenses pertaining to the said facility were included under the head project pre-operative expenses.

There are no separate reportable segments.

There is 1 investor complaint received during the quarter under review, complaint was resolved.

5) The figures for the Quarter ended 31/03/2014 are balancing figures between Audited figures in respect of the full Financial Year and the Published Year to date figures upto the 3rd Quarter of the relevant Financial Year.

For BACIL PHARMA LIMITED

Place:

Mumbai

Dated: May 30, 2014

BACIL PHARMA LIMITED

Regd. Off.: 71, LAXMI BUILDING, 4TH FLOOR, SIR P. M. ROAD, FORT, MUMBAI 400 001. Email ID: bacilpha@yahoo.com CIN: L24200MH1987PLC043427, Tel.: 22618452/22661541, Tel/Fax: 22618327

6.	Statement of Assets and Liabilities	As at 31 March, 2014	As at 31 March, 2013
EQUITY AN	ND LIABILITIES		
Shareholder	rs Funds	•	
c) Sh	are Capital	652.72	652.72
d) Re	serves and Surplus	- 3.02	7.88
	Subtotal Shareholders Funds	649.70	660.60
Non-current	t Liabilities		
c) Loi	ng-term borrowings		-
d) Loi	ng-term provisions		
	Subtotal Non-current Liabilities		
Current Liab	bilities	,	
e) Sh	ort-term borrowings	8.00	
f) Tra	ade payables		31.10
g) Otl	her current liabilities	0.38	1.01
h) Sh	ort-term provisions	0.55	0.77
•	Subtotal Current Liabilities	8.93	32.88
	TOTAL EQUITY AND LIABILITIES	658.63	693,48
ASSETS	•		
Non-current	t assets		
f) Fix	red assets	581.35	574.41
g) No	n-current investments	25.21	32.74
h) De	eferred tax assets (net)		
i) Lor	ng-term loans and advances		
j) Otl	her Non current assets		
	Subtotal Non-current Assets	606.56	607.15
Current Ass			
	rrent Investments		
	ventories		
	ade receivables	. 0.81	0.51
	sh and cash equivalents	8.54	13.48
,	ort-term loans and advances	19.92	49.53
I) Oti	her current assets	22.80	22.81
	Subtotal Current Assets	52.07	86.33
	TOTAL ASSETS	658.63	693.48

For BACIL PHARMA LIMITED

Place:

Mumbai

Dated:

May 30, 2014

Director

A. W. KETKAR & CO.

CHARTERED ACCOUNTANTS

4, Soukhya, V. N. Purav Marg, Chunabhatti, Mumbai 400 022. Mobile: 9820155435

To, Board of Directors Bacil Pharma Ltd. 71, Laxmi Building, 4th Floor, Sir P. M. Road, Fort, Mumbai – 400 001

Sub.: Auditors Report on Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Clause 41 of the Listing Agreement

We have audited the quarterly financial results of Bacil Pharma Ltd. for the quarter ended 31st March, 2014 and the year to date results for the period from 1st April, 2013 to 31st March, 2014 attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibilities of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, issued pursuant to the Companies (Accounting Standards) Rules, 2006 as per section 211 (3C) of the Companies Act, 1956 or by the Institute or Chartered Accountants of India and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
- II. give a true and fair view of the net loss and other financial information for the guarter ended 31st March, 2014.

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

Place: Mumbai Dated: May 30, 2014 Proprietor

Membership No.: 012287

4. *W. KETKAR & CO.*

ACCOUNTANTS